TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02488239

Intervention type: DEVICE
Intervention: CRT-P indicated patients
Description: Patients who are indicated for a CRT-P device are planned to be implanted with a CRT-P device
Study: NCT01891773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhaled steroids in school.
Description: Morning dose of inhaled steroids given in school by school nurse instead of at home.
Study: NCT01669460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Bull™ Sugar-Free Drink
Description: Red Bull™ Sugar-Free Drink two (250mL) cans per day for 28 days
Study: NCT03334058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-113
Description: human IgG1-derived Fc fragment that binds to human neonatal Fc receptor (FcRn)
Study: NCT00896688

Intervention type: PROCEDURE
Intervention: cervical medial branch blocks using the Quincke spinal needle
Description: #25 gauge 1 and 1/2 inch long needle and #25 gauge 10cm long Quincke spinal needle will be used for placement.

Intervention type: PROCEDURE
Intervention: cervical medial branch blocks using the Quincke spinal needle
Description: #25 gauge 1 and 1/2 inch long needle and #25 gauge 10cm long Quincke spinal needle will be used for placement.
Study: NCT01121601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic surgery of resection
Description: after metastasis liver resection , Coseal will be administered at 4 mL by dose, administration of 1 to 3 dose in fontion of liver adherence Coseal will be administered by spray at 5 to 10 cm of liver.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hepatic surgery of resection
Description: this is a liver metastasis resection according to liver chirurgical guidelines study drug not administered in this group
Study: NCT02458664

Intervention type: GENETIC
Intervention: Genetic analysis on tumor kept in tumor bank
Study: NCT03734861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreatheSmart System
Description: * BreatheSmart System: a mobile application that tracks medication usage and sends real time reminders~* HeroTracker sensor that counts dosage and monitors real-time medication adherence~* CoheroConnect provider portal that allows the Investigator to monitor adherence

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
Study: NCT04814160

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mixture of bioactive glass and autogenous bone graft
Description: bone expansion was performed and autogenous bone mixed with bioactive glass was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autogenous bone graft
Description: bone expansion was performed and autogenous bone alone was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants
Study: NCT01506622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of propofol
Description: Propofol 1 mg/kg will be administered to propofol group at the end of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of fentanyl
Description: Fentanyl 1 mcg/kg will be administered to fentanyl group at the end of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of saline
Description: Saline will be administered to control group at the end of anesthesia.
Study: NCT02482922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise & Dietary Supplement
Study: NCT00367133

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Group
Description: Standard of care group: conventional treatment consisting of focal/grid photocoagulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1mg triamcinolone acetonide
Description: Intravitreal injection of 1mg of triamcinolone acetonide at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg triamcinolone acetonide
Description: 4mg intravitreal triamcinolone acetonide injection at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
Study: NCT03893123

Intervention type: OTHER
Intervention: Observational study, prostate cancer is outcome of interest
Description: Observational study
Study: NCT02336074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination Antiretroviral Therapy (cART)
Description: Likely consisting of an Nucleoside reverse-transcriptase inhibitor (NRTI) backbone i.e. Truvada plus a ritonavir-boosted protease inhibitor (PI) e.g. Darunavir + ritonavir. Prescribed at week 0 for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Antiretroviral Therapy (cART)
Description: Likely consisting of an Nucleoside reverse-transcriptase inhibitor (NRTI) backbone i.e. Truvada plus a ritonavir-boosted protease inhibitor (PI) e.g. Darunavir + ritonavir. Prescribed at week 0 for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: All participants will be dispensed sufficient supplies of Raltegravir to ensure they have sufficient medication to last to the next study visit. Raltegravir is supplied in marketed pack with 30 tablets per bottle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: All participants will be dispensed sufficient supplies of Raltegravir to ensure they have sufficient medication to last to the next study visit. Raltegravir is supplied in marketed pack with 30 tablets per bottle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat (suberoylanilide hydroxamic acid abbreviated to SAHA) inhibits the histone deacetylases HDAC1, HDAC2, HDAC3 (Class I) and HDAC6 (Class II).~Vorinostat is supplied as capsules containing 100mg vorinostat and the following inactive ingredients: microcrystalline cellulose, sodium croscarmellose and magnesium stearate.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv (ChAd)
Description: Dosage: 5x1010vp .This dose is obtained by injecting 0.37ml of the vaccine at 1.35x1011vp/ml without dilution. This prime vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 00.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv (MVA)
Description: Dosage: 2x108pfu Administration: This dose is obtained by injecting 0.23 ml of the vaccine IM at 8.6x108pfu/ml without dilution. This boost vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 08 Day 1 (2 prior to start of vorinostat)
Study: NCT01252953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anacetrapib
Description: tablet, 100mg daily
Study: NCT04062604

Intervention type: OTHER
Intervention: surgery
Description: surgical treatment of femur fracture, hip and knee alloplasty, knee arthroscopy
Study: NCT01252953

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo anacetrapib
Description: tablet, 1 tablet daily
Study: NCT02915445

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EpCAM CAR-T cells
Description: Patients included will be infused the autologous T cells armed with CAR recognizing EpCAM. After infusion, cytokines and other medical test will be performed.
Study: NCT03264521

Intervention type: OTHER
Intervention: Surveys
Description: Web surveys about experiences with chronic low back pain, demographics, coding qualitative text.
Study: NCT02464657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Phase I Starting Dose of Nivolumab: 1 mg/kg by vein on Day 24 of a 28 day cycle.~Phase II Starting Dose of Nivolumab: Maximum tolerated dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Phase I Starting Dose of Nivolumab: 1 mg/kg by vein on Day 24 of a 28 day cycle.~Phase II Starting Dose of Nivolumab: Maximum tolerated dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Phase I Starting Dose of Nivolumab: 1 mg/kg by vein on Day 24 of a 28 day cycle.~Phase II Starting Dose of Nivolumab: Maximum tolerated dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-medrol
Description: Phase I and Phase II dose of Solu-medrol 50 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-medrol
Description: Phase I and Phase II dose of Solu-medrol 50 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-medrol
Description: Phase I and Phase II dose of Solu-medrol 50 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Phase I and Phase II dose of Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Phase I and Phase II dose of Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Phase I and Phase II dose of Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
Study: NCT01619241

Intervention type: OTHER
Intervention: PET/CT
Description: F-18 FLT PET/CT
Study: NCT03781102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 16-Week Diabetes Prevention Program for Mothers and Children
Description: The 16-week intervention is focused on ways to modify behaviors associated with the pathogenesis of Type 2 Diabetes in youth, while engaging participants in fun, active, and interactive food demonstrations, energy balance, and physical activities appropriate for all the family. Weekly sessions will consist of: (1) physical activity upon arrival; (2) small group discussions; (3) hands-on food preparation and tasting opportunities; (4) low- to no-cost fun family physical activities; (5) energy balance activities (e.g. label reading) to increase foundational knowledge; and, (6) opportunities to set new weekly goals.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 16-Week Diabetes Prevention Program for Mothers and Children
Description: The 16-week intervention is focused on ways to modify behaviors associated with the pathogenesis of Type 2 Diabetes in youth, while engaging participants in fun, active, and interactive food demonstrations, energy balance, and physical activities appropriate for all the family. Weekly sessions will consist of: (1) physical activity upon arrival; (2) small group discussions; (3) hands-on food preparation and tasting opportunities; (4) low- to no-cost fun family physical activities; (5) energy balance activities (e.g. label reading) to increase foundational knowledge; and, (6) opportunities to set new weekly goals.
Study: NCT03034356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Anticonvulsant drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Anticonvulsant drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04285268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT03459235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality of life
Description: Assessment of the impact of digestive sequelae (LARS score) and genitourinary sequelae (score IPSS, USP, FSFI et IIEF) in Patients With Rectal Cancer using validated questionnaires on quality of life (EORTC QLQ-C30 et QLQ-CR 29).
Study: NCT02125981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Limaprost
Description: taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: taking placebo drug
Study: NCT01803594

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Krill Oil
Description: Neptune Krill Oil Gold

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Krill Oil
Description: Neptune Krill Oil Gold

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein
Description: Jarrow Formulas

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein
Description: Jarrow Formulas

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinic acid
Description: Natures Way

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy phospholipids
Description: PC700 manufactured by Fonterra

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy phospholipids
Description: PC700 manufactured by Fonterra

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control shake without dietary supplements
Study: NCT04062604

Intervention type: OTHER
Intervention: surgery
Description: surgical treatment of femur fracture, hip and knee alloplasty, knee arthroscopy

Intervention type: OTHER
Intervention: surgery
Description: surgical treatment of femur fracture, hip and knee alloplasty, knee arthroscopy

Intervention type: OTHER
Intervention: surgery
Description: surgical treatment of femur fracture, hip and knee alloplasty, knee arthroscopy
Study: NCT02993432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter filled to 80cc
Description: A Foley catheter is inserted through the cervix and filled to 80cc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prostaglandin of the clinician's choice
Description: Insertion of the prostaglandin (Prostin (1mg dinoprostone vaginal gel) or Cervidil (10mg vaginal slow release insert)) of the clinicians choice into the vagina for the purpose of cervical ripening
Study: NCT01307618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NA17.A2 Peptide Vaccine
Description: Given SC or ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NA17.A2 Peptide Vaccine
Description: Given SC or ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant MAGE-3.1 Antigen
Description: Given SC or ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant MAGE-3.1 Antigen
Description: Given SC or ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interleukin-12
Description: Given SC or ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1 Antigen
Description: Given SC or ID

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01356056

Intervention type: DEVICE
Intervention: Kinesia HomeView
Description: Quantifies motor symptom severity in the home
Study: NCT04714580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal Fun Program
Description: This program permits the operators to propose different activities, by following the needing of the children. As the name of this program suggests, all the activities involve an animal description, and ask the children to move like this animal, in a proper, correct and supervised way.
Study: NCT03050463

Intervention type: PROCEDURE
Intervention: Functional Magnetic Resonance Imaging
Description: Undergo fMRI related tasks

Intervention type: PROCEDURE
Intervention: Functional Magnetic Resonance Imaging
Description: Undergo fMRI related tasks

Intervention type: PROCEDURE
Intervention: Functional Magnetic Resonance Imaging
Description: Undergo fMRI related tasks

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02480660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: The video highlights key elements found in the existing literature critical for transition including understanding and taking charge of their health, creating a medical summary, learning more about health insurance, introducing the idea of organizing a health care transition team and creating a plan. The video also educates patients on the opportunities to take a tour of an adult floor, talk with social workers and learn more about adult providers during their hospital stay.
Study: NCT03227276

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Litramine
Description: 2 tablets to be taken 3 times a day after meals

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 2 tablets to be taken 3 times a day after meals
Study: NCT03110627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VDD ICD (experimental group)
Description: Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single chamber VVI ICD (control group)
Description: Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications.
Study: NCT04618900

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus floor elevation with a grafting material
Description: The use of grafting material for sinus floor elevation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sinus floor elevation with a grafting material
Description: The use of grafting material for sinus floor elevation
Study: NCT03218787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE
Description: Subjects who received XIENCE family stent systems will be included.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPT
Description: 3-month clear subjects who receive 3-month DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for \> 7 consecutive days.~Subject who are 3-month clear will discontinue P2Y12 inhibitor after 3-month visit, but continue taking aspirin through 12-month follow-up. Subjects who are not eligible for early P2Y12 inhibitor discontinuation will be treated per site standard of care.
Study: NCT05281120

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-level mechanical vibrations WITH vertical sinusoidal acceleration
Description: Small platform designed to induce vertical, sinusoidal acceleration.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low-level mechanical vibrations WITHOUT vertical sinusoidal acceleration
Description: Small platform designed to NOT induce vertical, sinusoidal acceleration
Study: NCT01949324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ciliary neurotrophic factor (CNTF)
Description: Ciliary neurotrophic factor released from NT-501 encapsulated cell implant

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Sham surgery for Sham arm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NT-501 Implant
Description: NT-501 encapsulated cell implant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NT-501 Implant procedure
Description: Surgery to implant device for NT-501 encapsulated cell implant releasing human ciliary neurotrophic factor arm
Study: NCT01062490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: 14 g/m2/d, day -6 to -4